Kisqali, owned by Novartis, is an orally administered drug available as a tablet. This medication contains an active ingredient known as ribociclib succinate. Initially approved for market use on 13 March 2017, Kisqali is protected by 8 patents, none of which have expired to date.
The hypothetical release of Kisqali's generics hinges on the expiration of its many patents - the last of which is due to expire on 14 April 2036. Thus, we expect the generics to enter the market post this date.
Kisqali's active ingredient ribociclib succinate plays an integral role in its extensive use for combating breast cancer. The drug is primarily used as an endocrine-based therapy in combination with an aromatase inhibitor or fulvestrant. It is administered to pre/perimenopausal and postmenopausal women, as well as adult patients, with HR-positive, HER2-negative advanced, or metastatic breast cancer. It can be used initially or following disease progression on endocrine therapy.
Kisqali, a Novartis drug, enjoys the protection of several patents. The patent expiring last - US10799506 titled 'Ribociclib tablet' - will lapse on 14 April 2036. This effectively sets the earliest probable date for the release of Kisqali generics. Below are the details of the patent: